Renalytix annual r&d spending
2019
2020
2021
2022
2023
2024
2025
Renalytix R&D Spending Growth & History (RENX)
Renalytix's r&d spending was $900,000 for fiscal 2025.
View full Renalytix company overviewRenalytix annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-06-30 | $900,000 | −$8.4M | −90.31% |
| 2024 | 2024-06-30 | $9.3M | −$5.0M | −35.03% |
| 2023 | 2023-06-30 | $14.3M | −$350,000 | −2.39% |
| 2022 | 2022-06-30 | $14.6M | $4.6M | +45.90% |
| 2021 | 2021-06-30 | $10.0M | $5.5M | +119.93% |
| 2020 | 2020-06-30 | $4.6M | $249,000 | +5.77% |
| 2019 | 2019-06-30 | $4.3M | — | — |
Renalytix quarterly r&d spending
Q2.18
Q3.21
Q1.22
Q3.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q1 2025 | 2024-09-30 | $921,000 | −$1.9M | −66.95% |
| Q4 2024 | 2024-06-30 | $1.1M | −$2.2M | −67.54% |
| Q3 2024 | 2024-03-31 | $2.2M | −$1.7M | −43.80% |
| Q2 2024 | 2023-12-31 | $3.2M | −$101,000 | −3.04% |
| Q1 2024 | 2023-09-30 | $2.8M | −$970,000 | −25.82% |
| Q4 2023 | 2023-06-30 | $3.3M | — | — |
| Q3 2023 | 2023-03-31 | $3.9M | $56,000 | +1.44% |
| Q2 2023 | 2022-12-31 | $3.3M | — | — |
| Q1 2023 | 2022-09-30 | $3.8M | −$241,000 | −6.03% |
| Q3 2022 | 2022-03-31 | $3.9M | $783,000 | +25.23% |
| Q1 2022 | 2021-09-30 | $4.0M | — | — |
| Q3 2021 | 2021-03-31 | $3.1M | — | — |
| Q2 2018 | 2018-06-30 | $193,000 | — | — |
Renalytix r&d spending trends
Over the last five fiscal years, Renalytix's r&d spending decreased from $4.6M to $900,000, a change of −$3.7M. The latest reported quarter, Q1 2025, shows $921,000.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Renalytix source filings ↗